Alnylam Pharmaceuticals, Inc.
Serpina1 iRNA compositions and methods of use thereof

Last updated:

Abstract:

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Status:
Grant
Type:

Utility

Filling date:

11 Nov 2019

Issue date:

16 Jun 2020